Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;84(12):1128-1137.
doi: 10.1002/pros.24749. Epub 2024 Jun 2.

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA

Irena Abramovic  1   2   3 , Ivan Pezelj  4 , Leo Dumbovic  4 , Lucija Skara Abramovic  1   2   3 , Tonci Vodopic  5 , Stela Bulimbasic  6   7 , Goran Stimac  4 , Floriana Bulic-Jakus  1   3 , Tomislav Kulis  2   7   8 , Ana Katusic Bojanac  1   3 , Davor Tomas  9 , Monika Ulamec  2   3   7   9   10 , Nino Sincic  1   2   3   11
Affiliations

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA

Irena Abramovic et al. Prostate. 2024 Sep.

Abstract

Background: The unmet challenge in prostate cancer (PCa) management is to discriminate it from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research on potential PCa biomarkers is directed toward methylated cell-free DNA (cfDNA) from liquid biopsies since epigenetic mechanisms are strongly involved in PCa development.

Methods: In the present research, cfDNA methylation of the LGALS3 gene in blood and seminal plasma of PCa and BPH patients was assessed using pyrosequencing, as well as LGALS3 DNA methylation in tissue biopsies. Liquid biopsy samples were taken from patients with clinical suspicion of PCa, who were subsequently divided into two groups, that is, 42 with PCa and 55 with BPH, according to the histopathological analysis.

Results: Statistically significant higher cfDNA methylation of LGALS3 in seminal plasma of BPH than in PCa patients was detected by pyrosequencing. ROC curve analysis showed that it could distinguish PCa and BPH patients with 56.4% sensitivity and 70.4% specificity, while PSA did not differ between the two patient groups. In contrast, there was no statistically significant difference in LGALS3 cfDNA methylation in blood plasma between the two patient groups. In prostate tumor tissue, there was a statistically significant DNA hypermethylation of LGALS3 compared to surrounding nontumor tissue and BPH tissue.

Conclusions: The DNA hypermethylation of the LGALS3 gene represents an event specific to PCa development. In conclusion, LGALS3 cfDNA methylation in seminal fluid discriminates early PCa and BPH presenting itself as a powerful novel PCa biomarker highly outperforming PSA.

Keywords: DNA methylation; LGALS3; biomarkers; liquid biopsy; prostate cancer; seminal plasma.

PubMed Disclaimer

References

REFERENCES

    1. Wu YS, Wu XB, Zhang N, et al. Evaluation of PSA‐age volume score in predicting prostate cancer in Chinese population. Asian J Androl. 2018;20(4):324‐329.
    1. Opoku Mensah B, Fondjo LA, Owiredu WKBA, Adusei B. Urinary PCA3 a superior diagnostic biomarker for prostate cancer among Ghanaian men. Dis Markers. 2022;2022:1686991.
    1. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 1998;52(3):372‐378.
    1. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Goepel M, Tscholl R. Free‐to‐total prostate‐specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels. Br J Urol. 1998;81(4):532‐538.
    1. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68(4):297‐316.

MeSH terms